eNLife Research funding made headlines on 8 July 2026 as the Bengaluru-based deeptech startup secured ₹6 crore in a Seed round led by Piper Serica VC Fund, as publicly reported on 2026-07-08. The company is building an AI-powered blood biomarker platform designed to detect Alzheimer’s disease and other neurodegenerative disorders years before clinical symptoms emerge. The round marks the startup’s first disclosed external capital raise since its founding in 2025.
Quick Highlights
- Founders: Dr. Deepak Kumaran Nair (Co-founder & CEO, Professor at the Centre for Neuroscience, IISc), Lt. Col. Jojo Jacob, and Anish Mathew (former CEO, CAMS Finserv)
- Lead Investor: Piper Serica VC Fund
- Investor Background: Piper Serica VC Fund is the backer behind the recently launched ₹800 crore Bharat Tech Fund, which backs startups building proprietary technologies across AI, biosciences, semiconductors, defence technology, spacetech, and cybersecurity
- Headquarters: Bengaluru, Karnataka
- Incubator: Foundation for Science Innovation and Development (FSID) at the Indian Institute of Science (IISc)
- Announcement Date: 8 July 2026
Funding Breakdown
Use of Funds
As publicly reported, the ₹6 crore raised will be deployed across three primary areas. First, the company will build and validate its blood-based biomarker platform, advancing its first diagnostic assay from prototype stage to clinical-grade validation. Second, eNLife Research will expand its Bengaluru-based R&D team. Third, the startup expects to begin filing patents within the next 9 to 18 months, covering biomarker binders, diagnostic assays, and its proprietary detection platform. The broader stated objective is to make early Alzheimer’s detection affordable and accessible across India, including Tier II and Tier III regions.
Funding Timeline
This ₹6 crore Seed round is eNLife Research’s first publicly disclosed funding round. The company was co-founded in 2025 and is currently at Technology Readiness Level (TRL) 3–4, with proof of concept already demonstrated. It is currently a pre-revenue company.
Expansion Plans
eNLife Research plans to grow its R&D team in Bengaluru and deepen collaborations with researchers at IISc, the National Institute of Mental Health and Neurosciences (NIMHANS), the Tata Institute of Fundamental Research (TIFR) Hyderabad, and the Centre for Brain Research (CBR) Bengaluru, to build India-specific biomarker datasets. On the product side, the startup currently screens for a panel of five to seven biomarkers — including amyloid beta and abnormal tau proteins — and plans to eventually expand that panel to between 25 and 100 biomarkers to identify a broader range of neurodegenerative disorders. The company also plans to commercialise its technology through licensing, and its test is designed to be deployable through routine diagnostic centres, delivering results within two to five hours.
Significance
eNLife Research sits at a genuinely underserved intersection: existing diagnostic approaches for Alzheimer’s — such as PET scans, MRI scans, and cerebrospinal fluid analysis — are expensive, invasive, and typically identify the disease only one to two years before symptoms emerge, whereas eNLife’s AI engine is being trained to detect disease progression up to 15 years before clinical symptoms manifest. India’s rapidly ageing population makes this urgency particularly acute, as publicly reported comments from Piper Serica’s director Rajni Agarwal underscore: neurodegenerative disease is “the burden we are least prepared for.” What further distinguishes eNLife is its deliberate focus on Indian genetic and lifestyle risk profiles — an acknowledged gap, given that most existing diagnostic models were built on Western cohorts. For the broader Indian deeptech and healthtech ecosystem, this deal signals that early-stage, science-first diagnostics companies can attract institutional capital even before reaching revenue.
These details have been verified against multiple publicly available reports as of 2026-07-08.
Stay updated with the latest startup funding news on The Courtroom.
Disclaimer: This report is compiled from publicly available sources and is for informational purposes only; funding figures are as publicly reported and may be subject to change.
